Cue Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cue Biopharma, Inc. on October 1, 2021. The report details the entry into a new material definitive agreement for an equity offering and the termination of a prior sales agreement.
Key Financial Metrics and Transaction Details
- New Offering Capacity: The Company entered into an Open Market Sale Agreement with Jefferies LLC to sell up to $80,000,000 of common stock.
- Agent Compensation: The Company agreed to pay Jefferies LLC a commission of 3.0% of the gross proceeds from the sale of shares.
- Prior Offering Results: Under the terminated agreement with Stifel, Nicolaus & Company, Incorporated, the Company sold 2,099,700 shares for aggregate gross proceeds of $33.4 million.
- Liquidity and Debt: The filing text does not provide specific values for current cash balances, debt levels, or operating cash flow.
Material Changes Versus Prior Period
The primary material change is the replacement of the prior At-the-Market Equity Offering Sales Agreement (dated June 22, 2020) with Stifel, which allowed for up to $40.0 million in sales, with a new agreement with Jefferies LLC allowing for up to $80.0 million in sales. The prior agreement was terminated on September 24, 2021.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, revenue outlook, or management commentary regarding future operational performance. The offering is structured as an "at-the-market" offering, meaning the Company or the Agent may suspend or terminate the offering of shares upon notice to the other party. The sale of shares is subject to market conditions and the terms of the Sales Agreement.
Key Facts for Investor Verification
- Verify the current share price and the potential dilution impact of selling up to $80 million in new shares.
- Confirm the total number of shares outstanding post-transaction to assess ownership dilution.
- Review the Company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K does not provide liquidity metrics.
- Note that the new offering is subject to suspension or termination at the discretion of the Company or the Agent.